https://blog.naver.com/haruhan93/224466020640
📅 October 21, 2026 |
📚 Based on reporting by David Wainer, The Wall Street Journal
Investors are beginning to reconsider where they put their money.
After years of excitement surrounding artificial intelligence, healthcare stocks are attracting renewed attention.
The reason is simple: when investors become concerned about expensive technology stocks, they often look for businesses with more predictable earnings.
📈 1. Healthcare Is No Longer Cheap
About a year earlier, healthcare stocks traded at roughly a 25% valuation discount to the S&P 500.
That discount has disappeared.
According to the article, the Health Care Select Sector SPDR ETF (XLV) was trading at approximately 19.3 times expected earnings, slightly above the broader market.
This shift reflects growing investor interest in defensive sectors.
🤖 2. Why AI Anxiety Benefits Healthcare
AI infrastructure requires enormous investment in data centers, chips and energy.
Higher interest rates can make those investments more expensive.
If investors begin questioning whether AI spending will generate sufficient profits, they may seek alternatives.
Healthcare offers one important advantage: demand for medical treatment and essential medicines is generally less sensitive to economic cycles.
That does not make healthcare risk-free, but it can make the sector attractive during periods of uncertainty.
💊 3. Pharmaceutical Growth Remains Important
Two major companies illustrate the sector's growth potential.
Eli Lilly
The company was expected to increase 2026 revenue by more than 30%, supported by its diabetes and obesity treatments, Mounjaro and Zepbound.
Johnson & Johnson
The company was forecasting double-digit sales growth by the end of the decade, according to the article.
Together, these two companies represented approximately one-quarter of XLV.
🔍 4. Medical Devices May Offer Different Opportunities
Not every healthcare stock carries the same valuation.
Stryker, a medical-device manufacturer, was trading at approximately 18 times expected earnings, compared with its 10-year average of 24 times.
Investor concerns included difficulties in its joint-replacement business and softer demand.
Other medical-device companies, including Abbott and Zimmer Biomet, were also trading below historical valuation levels.
However, a lower valuation does not automatically indicate an attractive investment.
⚠️ 5. What History Can Teach Investors
The mid-2000s offer an interesting comparison.
During that period, rising interest rates and concerns about an overheated housing market created uncertainty.
Healthcare maintained relatively strong valuations.
When the financial crisis arrived, the sector declined less than the broader market and subsequently delivered an extended period of relative outperformance.
Still, historical similarities do not guarantee that the AI boom will end like the housing boom.
💡 6. Key Takeaways for Investors
✅ Healthcare is attracting attention as concerns about AI valuations increase.
✅ Demand for medical products and services can be relatively resilient.
✅ Pharmaceutical companies and medical-device manufacturers offer different growth and valuation profiles.
✅ Political uncertainty, earnings disappointments and high valuations remain important risks.
🎯 Final Thoughts
The rise in healthcare stocks may tell us something important about the broader market.
Investors are not necessarily abandoning AI. Instead, some are becoming more interested in balancing growth opportunities with businesses that may provide steadier earnings.
The question is not simply whether AI will succeed, but how much investors should pay for its expected success.
Which sector do you believe offers a better balance of growth and stability over the coming years: technology or healthcare?
Source: The Wall Street Journal, David Wainer, October 21, 2026.
This article is an independent educational commentary based on reported information and does not constitute investment advice.
